JNJ

170.71

-0.01%↓

ABBV

196.37

-1.09%↓

AZN

73.59

-1.13%↓

NVS

113.55

-3.58%↓

ABT

130.95

+0.14%↑

JNJ

170.71

-0.01%↓

ABBV

196.37

-1.09%↓

AZN

73.59

-1.13%↓

NVS

113.55

-3.58%↓

ABT

130.95

+0.14%↑

JNJ

170.71

-0.01%↓

ABBV

196.37

-1.09%↓

AZN

73.59

-1.13%↓

NVS

113.55

-3.58%↓

ABT

130.95

+0.14%↑

JNJ

170.71

-0.01%↓

ABBV

196.37

-1.09%↓

AZN

73.59

-1.13%↓

NVS

113.55

-3.58%↓

ABT

130.95

+0.14%↑

JNJ

170.71

-0.01%↓

ABBV

196.37

-1.09%↓

AZN

73.59

-1.13%↓

NVS

113.55

-3.58%↓

ABT

130.95

+0.14%↑

Kodu・Aktsiate loetelu・West Pharmaceutical Services Inc

West Pharmaceutical Services Inc

Suletud

SektorTervishoid

237.24 -1.02

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

233.23

Max

239.51

Põhinäitajad
By Trading Economics
Sissetulek	42M 132M
Müük	69M 767M
P/E Sektori keskmine	35.848 34.393
Aktsiakasum	1.45
Dividenditootlus	0.35
Kasumimarginaal	17.195
Töötajad	10,600
EBITDA	48M 199M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+29.26% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.35% 2.54%
Järgmine tulemuste avaldamine	23. okt 2025

Turustatistika
By TradingEconomics
Turukapital	2B 17B
Eelmine avamishind	238.26
Eelmine sulgemishind	237.24

Uudiste sentiment

By Acuity

50%

169 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

213.26 / 219.27 Toetus ja vastupanu

West Pharmaceutical Services Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. aug 2025, 22:24 UTC

Tulu

Suurimad hinnamuutused turgudel

Airbnb Logs 2Q Beat, But Investments Weigh on Margin Outlook -- Update

6. aug 2025, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Earnings, U.S. Tariffs -- Market Talk

6. aug 2025, 23:39 UTC

Market Talk

Gold Steady as Traders Assess Geopolitical, Tariff Developments -- Market Talk

6. aug 2025, 23:28 UTC

Tulu

Kakao 2Q Net Profit Beat FactSet-Compiled Consensus

6. aug 2025, 23:28 UTC

Tulu

Kakao 2Q Net KRW171.82B Vs. Net KRW87.15B >035720.SE

6. aug 2025, 23:28 UTC

Tulu

Kakao 2Q Oper Pft KRW185.93B Vs. Pft KRW133.96B >035720.SE

6. aug 2025, 23:28 UTC

Tulu

Kakao 2Q Rev KRW2.028T Vs. KRW2.005T >035720.SE

6. aug 2025, 23:14 UTC

Tulu

Fiserv, Shift4, Toast Stocks Tumble on Earnings. Analysts Are Optimistic Anyway. -- Barrons.com

6. aug 2025, 23:01 UTC

Tulu

United Overseas Bank 2Q Net Interest Income S$2.34B Vs. S$2.40B >U11.SG

6. aug 2025, 23:01 UTC

Tulu

United Overseas Bank 2Q Total Income S$3.47B Vs. S$3.48B >U11.SG

6. aug 2025, 23:00 UTC

Tulu

United Overseas Bank 2Q Net S$1.34B Vs. Net S$1.43B >U11.SG

6. aug 2025, 22:54 UTC

Market Talk

New Zealand Companies Should Avoid Qualifying Profit Improvement -- Market Talk

6. aug 2025, 22:41 UTC

Tulu

DBS 2Q Allowances for Credit, Other Losses S$133.0M Vs. S$148.0M >D05.SG

6. aug 2025, 22:38 UTC

Tulu

DBS 2Q Net Interest Income S$3.63B Vs. S$3.77B >D05.SG

6. aug 2025, 22:38 UTC

Tulu

DBS 2Q Total Income S$5.73B Vs. S$5.48B >D05.SG

6. aug 2025, 22:38 UTC

Tulu

DBS 2Q Net S$2.82B Vs. Net S$2.80B >D05.SG

6. aug 2025, 22:28 UTC

Market Talk

NZX Bear Says Growth Likely to Miss Market's Hopes -- Market Talk

6. aug 2025, 22:11 UTC

Tulu

Pan American Silver 2Q Rev $811.90 >PAAS

6. aug 2025, 22:11 UTC

Tulu

Pan American Silver Raises Dividend to 12c >PAAS

6. aug 2025, 22:11 UTC

Tulu

Pan American Silver 2Q EPS 52c >PAAS

6. aug 2025, 22:03 UTC

Tulu

Nutrien 2Q Sales $10.44B >NTR.T

6. aug 2025, 22:03 UTC

Tulu

Nutrien: Nitrogen Sales Volume Guidance of 10.7MMT to 11.2MMT Assumes Lower Ammonia Operating Rates in 2H Compared to Record Achieved in 1H Due to Planned Turnaround Activity a North Amer Plants >NTR.T

6. aug 2025, 22:03 UTC

Tulu

Nutrien: Phosphate Sales Volume Guidance of 2.35MMT to 2.55MMT Assumes Improved Operating Rates, Sales Volumes in 2H Compared to Prior Yr With Completion of Planned Turnarounds in 1H >NTR.T

6. aug 2025, 22:03 UTC

Tulu

Nutrien: Potash Sales Volume Guidance Was Increased to 13.9MMT to 14.5MMT Due to Expectations for Higher Global Demand in 2025 >NTR.T

6. aug 2025, 22:03 UTC

Tulu

Nutrien 2Q EPS $2.50 >NTR.T

6. aug 2025, 22:03 UTC

Omandamised, ülevõtmised, äriostud

A Family Feud Leaves the Future of This Kefir -2-

6. aug 2025, 22:03 UTC

Omandamised, ülevõtmised, äriostud

A Family Feud Leaves the Future of This Kefir King in Doubt. Danone May Take Over. -- Barrons.com

6. aug 2025, 22:00 UTC

Market Talk

Tulu

Airbnb 2Q Results Overshadowed by EBITDA Outlook -- Market Talk

6. aug 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

Parataxis Holdings: Combines Bitcoin Exposure, Proprietary Growth Opportunities, Accretive Yield Generation >SBXD

6. aug 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

Parataxis Holdings: Once Proposed Transaction Is Closed, Combined Co Will Be Named Parataxis Holdings Inc. and Seek to Trade on NYSE Under the Symbol 'PRTX' >SBXD

Võrdlus sarnastega

Hinnamuutus

West Pharmaceutical Services Inc Prognoos

Hinnasiht

By TipRanks

29.26% tõus

12 kuu keskmine prognoos

Keskmine 308.75 USD 29.26%

Kõrge 350 USD

Madal 245 USD

Põhineb 9 Wall Streeti analüütiku instrumendi West Pharmaceutical Services Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi West Pharmaceutical Services Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

213.26 / 219.27Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

169 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.